V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10002503 | 10001643 | null | 62 | Palliative (P) | 2016-09-07 | 2016-09-14 | PEMBROLIZUMAB | N | N | 10436732 | PEMBROLIZUMAB |
| 10002504 | 10001643 | 1.61 | 97.5 | Palliative (P) | null | 2018-02-12 | CVP R | 2 | N | 10436732 | CVP R |
| 10002505 | 10001644 | 1.71 | 62 | Palliative (P) | null | 2015-08-07 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | Y | 10436781 | GEMCITABINE |
| 10002506 | 10001645 | 1.81 | 64.5 | Palliative (P) | 2016-07-24 | 2016-07-24 | Rituximab | 02 | null | 10436793 | RITUXIMAB |
| 10002507 | 10001646 | 1.53 | 50.2 | Neo-adjuvant (N) | 2016-09-03 | 2016-09-14 | GO2 TRIAL | 1 | N | 10436817 | TRIAL |
| 10002508 | 10001647 | 1.78 | 71.3 | null | 2015-02-07 | 2015-02-22 | Carboplatin + Vinorelbine Oral | N | N | 10436835 | CARBOPLATIN + VINORELBINE |
| 10002509 | 10001648 | null | null | Palliative (P) | 2017-10-13 | 2017-10-13 | Rituximab | 02 | N | 10436886 | RITUXIMAB |
| 10002510 | 10001648 | null | null | Curative (C) | 2017-07-13 | 2017-07-15 | Hydroxycarbamide | 02 | N | 10436886 | HYDROXYCARBAMIDE |
| 10002511 | 10007986 | 1.75 | 89 | Adjuvant (A) | 2017-07-19 | 2017-07-25 | Carboplatin + Vinorelbine IV | 02 | N | 10436903 | CARBOPLATIN + VINORELBINE |
| 10002512 | 10001649 | 1.73 | 77.7 | Curative (C) | 2017-05-30 | 2017-05-30 | Hydroxycarbamide | N | N | 10436952 | HYDROXYCARBAMIDE |
| 10002513 | 10001649 | 1.62 | 49.5 | Disease modification (D) | 2018-12-28 | 2018-12-29 | Rituximab | N | N | 10436952 | RITUXIMAB |
| 10002514 | 10001650 | 1.72 | 44 | Palliative (P) | 2017-03-29 | 2017-03-29 | Enzalutamide | N | null | 10437037 | ENZALUTAMIDE |
| 10002515 | 10001651 | null | 96.5 | Disease modification (D) | 2018-06-13 | 2018-06-13 | CVP R | N | N | 10437050 | CVP R |
| 10002516 | 10001651 | 1.76 | 83.7 | Adjuvant (A) | 2015-05-17 | 2015-05-18 | Hydroxycarbamide | N | N | 10437050 | HYDROXYCARBAMIDE |
| 10002517 | 10001651 | 1.68 | 74.2 | Palliative (P) | 2015-08-30 | 2015-08-30 | Trial Unspecified | 01 | N | 10437050 | TRIAL |
| 10002518 | 10001652 | 1.82 | 137.4 | Palliative (P) | 2015-04-17 | 2015-04-30 | Cisplatin + Pemetrexed | N | N | 10437089 | CISPLATIN + PEMETREXED |
| 10002519 | 10001652 | 1.55 | 46.6 | Palliative (P) | 2017-06-06 | 2017-06-12 | ECX | 02 | N | 10437089 | ECX |
| 10002520 | 10001653 | 1.66 | 81.1 | Palliative (P) | 2015-01-26 | 2015-01-27 | Rituximab | 2 | N | 10437126 | RITUXIMAB |
| 10002521 | 10001654 | 1.8 | 76 | Disease modification (D) | 2017-02-10 | 2017-02-14 | Hydroxycarbamide | 2 | N | 10437148 | HYDROXYCARBAMIDE |
| 10002522 | 10006217 | 1.71 | null | Disease modification (D) | 2017-06-18 | 2016-12-21 | Cisplatin + Pemetrexed | 02 | N | 10437181 | CISPLATIN + PEMETREXED |
| 10002523 | 10006217 | 1.73 | null | Palliative (P) | 2017-08-14 | 2017-08-21 | EOX | N | N | 10437181 | EOX |
| 10002524 | 10001655 | 1.57 | null | Disease modification (D) | 2018-03-12 | 2018-03-12 | Hydroxycarbamide | 02 | N | 10437290 | HYDROXYCARBAMIDE |
| 10002525 | 10001656 | null | 77 | Palliative (P) | 2018-08-03 | 2018-08-12 | CVP R | N | N | 10437303 | CVP R |
| 10002526 | 10001656 | null | 88 | Adjuvant (A) | 2017-09-17 | 2017-10-04 | Carboplatin + Vinorelbine Oral | 02 | N | 10437303 | CARBOPLATIN + VINORELBINE |
| 10002527 | 10001657 | 1.69 | 0 | Adjuvant (A) | 2017-03-25 | 2017-03-26 | Carboplatin + Vinorelbine IV | 2 | N | 10437409 | CARBOPLATIN + VINORELBINE |
| 10002528 | 10007989 | 1.95 | 84 | null | 2015-12-21 | 2015-12-22 | Cisplatin + Pemetrexed | N | N | 10437468 | CISPLATIN + PEMETREXED |
| 10002529 | 10001658 | 1.67 | 65 | Disease modification (D) | 2016-12-03 | 2016-12-05 | Hydroxycarbamide | 02 | N | 10437469 | HYDROXYCARBAMIDE |
| 10002530 | 10001658 | 1.69 | 0 | Palliative (P) | 2017-09-01 | 2017-09-28 | Cisplatin + Pemetrexed | N | N | 10437469 | CISPLATIN + PEMETREXED |
| 10002531 | 10001659 | 1.75 | 72 | Not known (9) | 2015-11-10 | 2015-11-16 | Cisplatin + Vinorelbine (IV) | N | null | 10437537 | CISPLATIN + VINORELBINE |
| 10002532 | 10001660 | 1.62 | 67 | Adjuvant (A) | 2015-12-04 | 2015-12-18 | Carboplatin + Vinorelbine Oral | 02 | N | 10437559 | CARBOPLATIN + VINORELBINE |
| 10002533 | 10001661 | 1.72 | 78 | Palliative (P) | 2015-06-16 | 2015-07-05 | Carboplatin + Vinorelbine Oral | N | null | 10437569 | CARBOPLATIN + VINORELBINE |
| 10002534 | 10001662 | 1.65 | 70.6 | Curative (C) | 2017-07-02 | 2017-07-15 | CVP R | 2 | N | 10437652 | CVP R |
| 10002535 | 10001662 | 1.61 | 102 | Disease modification (D) | 2018-05-01 | 2018-05-04 | CVP R | 2 | N | 10437652 | CVP R |
| 10002536 | 10001662 | 1.53 | null | Palliative (P) | 2016-02-02 | 2016-02-23 | CVP R | N | N | 10437652 | CVP R |
| 10002537 | 10001663 | null | 62.1 | Palliative (P) | 2018-11-22 | 2018-12-07 | Cisplatin + Pemetrexed | N | N | 10437758 | CISPLATIN + PEMETREXED |
| 10002538 | 10006221 | 1.55 | null | Not known (9) | 2017-01-30 | 2017-02-18 | EOX | N | null | 10437819 | EOX |
| 10002539 | 10007991 | 1.65 | 57.3 | Palliative (P) | 2017-09-19 | 2017-09-19 | PEMBROLIZUMAB | 2 | N | 10437932 | PEMBROLIZUMAB |
| 10002540 | 10001664 | 1.64 | 0 | Disease modification (D) | 2018-02-19 | 2018-03-03 | Rituximab | 02 | N | 10437936 | RITUXIMAB |
| 10002541 | 10001665 | 1.8 | 69.5 | Palliative (P) | 2016-01-10 | 2016-01-17 | EOX | N | N | 10437979 | EOX |
| 10002542 | 10001665 | 1.77 | 68 | Adjuvant (A) | 2015-05-19 | 2015-05-19 | Carboplatin + Vinorelbine Oral | N | N | 10437979 | CARBOPLATIN + VINORELBINE |
| 10002543 | 10001666 | 2 | 62 | null | 2018-10-09 | 2018-10-17 | ECX | 02 | Y | 10438022 | ECX |
| 10002544 | 10001667 | 0 | 62 | Palliative (P) | 2018-08-14 | 2018-08-23 | Enzalutamide | 02 | N | 10438074 | ENZALUTAMIDE |
| 10002545 | 10001667 | 1.7 | 84 | Palliative (P) | null | 2015-12-04 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 10438074 | GEMCITABINE |
| 10002546 | 10001668 | 1.78 | 75 | Palliative (P) | 2016-10-07 | 2016-10-17 | PEMBROLIZUMAB | 02 | N | 10438117 | PEMBROLIZUMAB |
| 10002547 | 10001669 | 1.78 | 82 | Neo-adjuvant (N) | 2015-10-20 | 2015-10-28 | Cisplatin + Vinorelbine (PO) | 02 | N | 10438121 | CISPLATIN + VINORELBINE |
| 10002548 | 10001670 | 1.8 | 111 | Curative (C) | 2016-09-20 | 2016-09-26 | Cisplatin + Vinorelbine (IV) | N | N | 10438124 | CISPLATIN + VINORELBINE |
| 10002549 | 10001671 | 1.8 | null | Palliative (P) | null | 2016-07-02 | Trial Unspecified | 01 | N | 10438173 | TRIAL |
| 10002550 | 10001672 | 1.57 | 72.7 | Palliative (P) | 2019-01-15 | 2019-01-22 | PEMBROLIZUMAB | N | N | 10438182 | PEMBROLIZUMAB |
| 10002551 | 10001673 | 1.57 | 71.9 | Palliative (P) | 2017-07-26 | 2017-07-26 | Hydroxycarbamide | N | N | 10438185 | HYDROXYCARBAMIDE |
| 10002552 | 10001674 | 1.53 | null | Palliative (P) | 2017-08-23 | 2017-09-24 | Enzalutamide | N | N | 10438206 | ENZALUTAMIDE |